Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus Nivolumab in Advanced Solid Tumors
NCT04165330Phase 2Active, not recruiting
- Sponsor
- Cancer Institute Medical Group
- Start
- Oct 2019
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in solid tumor, soft tissue sarcoma (STS), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), sponsored by Cancer Institute Medical Group. Started Oct 2019; status: active, not recruiting.
02
Drugs
anlotinib
03
Conditions
solid tumorsoft tissue sarcoma (STS)non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04165330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04165330.